Bioray Biotech Appoints Dr. Yu Xiang, Former Greater China President of Santen Pharmaceutical, as CEO

On January 8, BRL Medicine announced,Dr. Xiang Yu officially joined BRL Medicine on January 1, 2026, serving as the Chief Executive Officer (CEO) of the company.Xiang Yu JiangFully responsible for the company's strategic planning, resource allocation, and overall operational management., leading BRL Medicine to achieve high-quality development during the critical phase of a comprehensive upgrade in "globalization, commercialization, and industrialization," and accelerating the clinical translation and market implementation of multiple cutting-edge gene and cell therapy products worldwide.

In response,Founder and Chairman of BRL MedicineLiu MingyaoThe professor said："The gene and cell therapy industry is currently entering a golden period of rapid development. BRL Medicine is at a critical stage of accelerating the development of multiple gene editing and cell therapy pipelines, advancing the clinical progress of core projects, and laying out a global commercialization strategy. We urgently need a leader with global vision, business acumen, and exceptional leadership to guide the company into a new journey. We look forward to Dr. Xiang Yu (向宇) leading the company to accelerate clinical translation and commercial implementation, enabling more patients worldwide to benefit from breakthrough therapies brought by gene editing technology."

Public information shows that,Xiang Yu's career began withMcKinseyThe company has a background in strategic consulting in the healthcare field. During his time at Novartis, he served as the Global Head of Strategy and held leadership roles in multiple business units in the China region. He also served as the General Manager of Abbott's diabetes business in Greater China and Emerging Asia.

Afterward, he assumed a position at BRL Medicine Inc.Langyu GroupCEO，Comprehensively lead the company's strategy, R&D, and commercialization, with experience in the launch of orphan drugs and their inclusion in medical insurance.

JoinBRL MedicinePreviously, Xiang Yu served as the President of Santen Pharmaceutical (China), fully responsible for the overall business operations and management of Santen's largest overseas market.。